| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 02/26/2004 | WO2002006480A3 Tissue inhibitors of matrix metalloproteinases |
| 02/26/2004 | US20040040052 Transgenic organism |
| 02/26/2004 | US20040040049 Reduction in the formation of the complex in the presence of the candidate agent as compared with in the absence of candidate agent indicates the candidate agent inhibits the binding of LBP-2 to the LBP-2 binding molecule |
| 02/26/2004 | US20040040047 Regulated apoptosis using chemically induced dimerization of apoptosis factors |
| 02/26/2004 | US20040039187 Chimeric GB virus B (GBV-B) |
| 02/26/2004 | US20040039186 Self-regulated apoptosis of inflammatory cells by gene therapy |
| 02/26/2004 | US20040039184 Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof |
| 02/26/2004 | US20040039165 Clostridium difficile polypeptides and uses thereof |
| 02/26/2004 | US20040038925 Inhibition of complement activation and complement modulation by use of modified oligonucleotides |
| 02/26/2004 | US20040038924 Adenovirus serotype 30 (Ad30) |
| 02/26/2004 | US20040038921 Comprises double-stranded oligoribonucleic acid (dsRNA); hammerhead ribozymes |
| 02/26/2004 | US20040038920 Which stimulate lymphoctyes specific for myelin basic protein (MBP) autoantigen, which induces severe experimental autoimmune encephalomyelitis in animal models; cytokines |
| 02/26/2004 | US20040038919 Novel gene therapy agent for haemophilia b and its preparation method |
| 02/26/2004 | US20040038918 Modified pituitary gland development in offspring from expectant mother animals treated with growth hormone releasing hormone therapy |
| 02/26/2004 | US20040038917 Such as urinary bladder tissue; immunoassays |
| 02/26/2004 | US20040038902 For therapy of neoplastic disease |
| 02/26/2004 | US20040038888 Functional role and potential therapeutic use of PACAP, VIP and Maxadilan in relation to adult neural stem or progenitor cells |
| 02/26/2004 | US20040038886 Chimeric cytoplasmic signalling molecules derived from cd137 |
| 02/26/2004 | US20040038882 Sgk2 and sgk3 used as diagnostic and therapeutic targets |
| 02/26/2004 | US20040038879 For therapy and prophylaxis of infections such as bacterial, fungal, protozoan, and viral infections, particularly those caused by HIV viruses, pain, cancers, anorexia, bulimia, asthma, Parkinson's disease, acute heart failure |
| 02/26/2004 | US20040038870 Methods of drug delivery using sulphated chitinous polymers |
| 02/26/2004 | US20040038869 Inhibitors of complement activation, their preparation and use |
| 02/26/2004 | US20040038410 Composition for the preservation of viruses |
| 02/26/2004 | US20040038406 Nanoparticle delivery systems and methods of use thereof |
| 02/26/2004 | US20040038403 Replication-defective; does not rely on use of tumor specific promoters |
| 02/26/2004 | US20040038402 Gene therapy; for production of transgenic animal models |
| 02/26/2004 | US20040038399 For preventing gene transcription/expression; for inducing nuclease stability, hybridization to complementary RNA sequences, permeability to oligonucleotides into cells, RNase cleavage, and blocking ribosome translocation |
| 02/26/2004 | US20040038396 Antihemophilic factor (factor VIII) |
| 02/26/2004 | US20040038393 Comprises alkaline lysis, concentration by precipitation with isopropanol, pre-purification/conditioning with ammonium sulphate, then adding buffer; solid phase synthesis; gene therapy; vaccines |
| 02/26/2004 | US20040038364 Such as snake venom proteases; anticoagulants |
| 02/26/2004 | US20040038341 Chimeric human-type vascular endothelial cell growth factor |
| 02/26/2004 | US20040038339 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| 02/26/2004 | US20040038325 Adhesion molecules |
| 02/26/2004 | US20040038303 Comprises use of small particle with appropriate hydrophilic-lipophilic-balance value to deliver anticarcinogenic agents to cells and/or tissues; drug screening |
| 02/26/2004 | US20040038298 Protein fragment complementation assays for the detection of biological or drug interactions |
| 02/26/2004 | US20040038297 Masp-2,a complement-fixing enzyme, and uses for it |
| 02/26/2004 | US20040038292 Comprises nucleotide sequences which code wound healing proteins for treatment and prevention of scarring, fibrosis, restenosis post angioplasty, psoriasis, benign prostatic hyperplasia, glaucoma and nervous suystem disorders |
| 02/26/2004 | US20040038284 Using replication error phenotype (RER) to classify and prognose tumor disorders; immunoassay |
| 02/26/2004 | US20040038278 Methods and compositions relating to gene silencing |
| 02/26/2004 | US20040038275 Human frezzled-like protein |
| 02/26/2004 | US20040038274 Gapped 2' modified oligonucleotides |
| 02/26/2004 | US20040038271 Novel C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof |
| 02/26/2004 | US20040038265 Using low density lipoprotein related proteins (LRP) to diagnose, treat and prevent paget's, osteoporosis, cirrhosis and rickets |
| 02/26/2004 | US20040038257 Therapeutic peptidase for diagnosis, treatment and prevention of cancer and nervous system disorders |
| 02/26/2004 | US20040038248 Novel polypeptide-human heterogeneous nuclear ribonucleoprotein 32.01 and the polynucleotide encoding said polypeptide |
| 02/26/2004 | US20040038247 Expression vector comprised of regulatory sequences for lymphocyte specific expression of heterologous polypeptides |
| 02/26/2004 | US20040038243 P53-dependent apoptosis-associated protein and method of screening apoptosis controlling agent |
| 02/26/2004 | US20040038236 Mutation associated with epilepsy |
| 02/26/2004 | US20040038230 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 02/26/2004 | US20040038223 Comprise polypeptide for diagnosis, prevention and treatment of cardiomyopathy, atherosclerosis, hypertension, cancer, diabetes and nervous system disorders |
| 02/26/2004 | US20040038215 Oligonucleotide tagged nucleoside triphosphates (OTNTPs) for genetic analysis |
| 02/26/2004 | US20040038209 Comprises nucleotide sequences coding beta -carotene dioxygenase which cleaves beta carotene and produces vitamin a aldehyde; improving nutritional value of plants, microorganisms and animal feeds |
| 02/26/2004 | US20040038205 Modified adenoviral fiber and uses |
| 02/26/2004 | US20040038204 Replacing worn wear strip associated with viral and nonviral gene delivery systems; gene therapy |
| 02/26/2004 | US20040038203 Comprises nucleotide sequences coding yaba monkey tumor viral protein for treatment and prevention of autoimmune diseases |
| 02/26/2004 | US20040037874 Delivery of nucleic acid-like compounds |
| 02/26/2004 | US20040037842 Compositions and methods for the therapy and diagnosis of colon cancer |
| 02/26/2004 | US20040037837 For stimulating CD8 T-cell response; tuberculosis vaccines; antigen presenting cells |
| 02/26/2004 | US20040037832 Transcription factor as repressor of expression of E-cadherin; detecting galactosidase activity; drug screening |
| 02/26/2004 | US20040037829 For immunoregulation and/or treatment of inflammation; muteins |
| 02/26/2004 | US20040037821 For expression of erythropoietin; genetic translocation; zinc finger motifs |
| 02/26/2004 | US20040037819 Non-polymeric hematopoeitic cell clots for delivery of active agents |
| 02/26/2004 | US20040037818 Treatment for diabetes |
| 02/26/2004 | US20040037817 Deleting lympocytes and reactivating thymus via CD34-antigens and/or leutininzing hormone releasing hormone agonists (sex steroids); for alleviation of autoimmune diseases and allergies |
| 02/26/2004 | US20040037816 Graft acceptance through manipulation of thymic regeneration |
| 02/26/2004 | US20040037780 Delivery of an exogenous gene to the respiratory epithelium in a lentiviral expression vector. Includes the preconditioning of the respiratory tract with a penetrating agent such as a detergent to cause tolerable transient damage |
| 02/26/2004 | DE10237639A1 Preparing virus-like particles, useful as gene therapy vectors, comprises assembling capsomers, optionally with active molecules attached, in presence of nonionic stabilizers |
| 02/26/2004 | DE10237517A1 Removing biomolecules from liquid media, useful for purification, product recovery or preparation of vectors, comprises retention on hydrotalcite of controlled porosity |
| 02/26/2004 | CA2535748A1 Pthrp-derived modulators of smooth muscle proliferation |
| 02/26/2004 | CA2497304A1 Bmp-2 estrogen responsive element and methods of using the same |
| 02/26/2004 | CA2496048A1 Use of murine genomic regions identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer |
| 02/26/2004 | CA2495824A1 Ex-vivo expansion of hematopoietic stem cell populations in mononuclear cell cultures |
| 02/26/2004 | CA2495185A1 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| 02/26/2004 | CA2494971A1 Heteropolymeric compound comprising a scaffold, an adjuvant and an antigen, and its use |
| 02/26/2004 | CA2494887A1 Modified tailed oligonucleotides |
| 02/26/2004 | CA2494847A1 Enos mutants useful for gene therapy |
| 02/26/2004 | CA2494845A1 Gene therapy for critical limb ischemia with wild type or mutant enos |
| 02/26/2004 | CA2493753A1 Immunostimulatory nucleic acids |
| 02/25/2004 | EP1391516A1 Von willebrand factor (vwf)-cleaving enzyme |
| 02/25/2004 | EP1391514A1 Pharmaceutical composition for treatment of angiogenesis-dependent conditions |
| 02/25/2004 | EP1391511A1 Artificial human chromosome containing human antibody lambda light chain gene |
| 02/25/2004 | EP1391214A1 Gene transfer of angiogenic factor for skin disease |
| 02/25/2004 | EP1390547A1 Antisense modulation of interleukin 12 p35 subunit expression |
| 02/25/2004 | EP1390543A2 New polynucleotides and polypeptides of the ifnalpha-17 gene |
| 02/25/2004 | EP1390518A2 Buffer solution for electroporation and a method comprising the use of the same |
| 02/25/2004 | EP1390516A1 Novel expression vectors and uses thereof |
| 02/25/2004 | EP1390512A1 A method for transfection of rna using electrical pulses |
| 02/25/2004 | EP1390508A2 A retinoic acid metabolizing cytochrome p450 |
| 02/25/2004 | EP1390502A2 Interferon-alpha induced gene |
| 02/25/2004 | EP1390497A2 Human cdnas and proteins and uses thereof |
| 02/25/2004 | EP1390496A2 Glutamate receptor modulatory proteins and nucleic acids encoding them |
| 02/25/2004 | EP1390495A2 Immunostimulatory oligodeoxynucleic molecules |
| 02/25/2004 | EP1390494A2 Method for stabilising of nucleic acids |
| 02/25/2004 | EP1390493A1 Antisense oligonucleotide against human acetylcholinesterase (ache) and uses thereof |
| 02/25/2004 | EP1390490A2 Muscle-specific expression vectors |
| 02/25/2004 | EP1390468A2 Identification of essential genes of aspegillus fumigatus and methods of use |
| 02/25/2004 | EP1390403A2 Peptides derived from neural thread proteins and their medical use |
| 02/25/2004 | EP1390400A2 Pharmaceutical use for secreted bacterial effector proteins |
| 02/25/2004 | EP1390398A2 Adenovirus protein ix, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization |
| 02/25/2004 | EP1390385A2 Nucleic acid based modulation of female reproductive diseases and conditions |